"Less Bleeding With Ticagrelor Alone In High-Risk Patients"
Ticagrelor alone results in less bleeding than ticagrelor plus aspirin among high-risk patients who have undergone percutaneous coronary intervention (PCI) and received dual antiplatelet therapy for three months, according to researchers at the Icahn School of Medicine at Mount Sinai. According to study author Roxana Mehran, MD, director of interventional cardiovascular research and clinical trials at the Zena and Michael A. Weiner Cardiovascular Institute at the Icahn School of Medicine at Mount Sinai, “A transition to an antiplatelet strategy of treatment with ticagrelor alone after a three-month course of dual antiplatelet therapy in high-risk patients who had undergone PCI provided a clinical benefit of less bleeding without ischemic harm.”
— Roxana Mehran, MD, Director, Interventional Cardiovascular Research and Clinical Trials, The Zena and Michael A. Weiner Cardiovascular Institute, Professor, Medicine, Cardiology, Population Health Science and Policy, Icahn School of Medicine at Mount Sinai
Additional coverage: Physician’s Weekly